Precigen Inc. reported its Q1 2026 earnings, showcasing better-than-expected financial performance. The company reported an EPS of -$0.02, exceeding the forecasted -$0.03, and achieved a revenue of $23.25 million, surpassing expectations of $20.8 million.
Following the earnings announcement, Precigen's stock surged by 10.84% in aftermarket trading, reflecting investor optimism. The company benefited from the commercial success of PAPZIMEOS, which generated $21.6 million in net product revenue.
CEO Helen Sabzevari highlighted the 'exceptional commercial viability' of PAPZIMEOS. The company expects to achieve cash flow break-even by the end of 2026.
